Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Short-term refractive and ocular parameter changes after topical atropine

Poster Details

First Author: H. Cheng TAIWAN

Co Author(s):    M. Ho   Y. Hsieh                 

Abstract Details


To explore short term refractive and ocular parameter changes and their correlations after cycloplegia with atropine.


a prospective study conducted in Taipei Tzu-Chi Hospital


Ninety-six left eyes of 96 participants were enrolled (mean age 8.5±2.1 years) in this study. Spherical equivalent of refractive error (SER), axial length (AL), corneal curvature (CC), anterior chamber depth (ACD) and intraocular pressure (IOP) were measured before and after one-week topical use of 0.125% atropine eye drop. A partial optical coherence interferometry (Zeiss IOLMaster) was used for ocular parameter measurement. Refractive change and ocular parameter changes after cycloplegia and their correlations were evaluated.


After topical atropine use, the mean AL decreased by 0.016 mm (p = 0.008) and the mean ACD increased by 0.58 mm (p < 0.0001). There was no significant change in CC or IOP. Eighty two eyes (85%) had emmetropic or hyperopic shift, while 14 had myopic shift. Those with emmetropic or hyperopic shift had their mean AL shortened by 0.023 mm, while the myopic-shifted eyes had their mean AL lengthened by 0.026 mm (P = 0.003) after using topical atropine. AL shortening (-2.57 diopter / mm, P = 0.0007) and ACD increase (0.96 diopter / mm, p = 0.013) were both correlated to the hyperopic changes after cycloplegia with atropine.


Most eyes had emmetropic or hyperopic changes after cycloplegia by topical atropine, while some had myopic changes. AL shortening and anterior chamber deepening both contributed to the hyperopic changes after topical atropine use.

Financial Disclosure:


Back to Poster listing